A share price of Centessa Pharmaceuticals plc ADR [CNTA] is currently trading at $16.46, up 1.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CNTA shares have gain 10.69% over the last week, with a monthly amount drifted -4.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley upgraded its rating to Overweight on September 20, 2024, and elevated its price target to $26. On September 19, 2024, B. Riley Securities initiated with a Buy rating and assigned a price target of $33 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $14 on July 18, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $11 on November 15, 2023. Morgan Stanley upgraded its rating to Equal-Weight for this stock on October 26, 2023, and upped its price target to $8. In a note dated June 21, 2023, Evercore ISI initiated an Outperform rating.
Centessa Pharmaceuticals plc ADR experienced fluctuations in its stock price throughout the past year between $7.38 and $18.97. Currently, Wall Street analysts expect the stock to reach $23.25 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $16.46 at the most recent close of the market. An investor can expect a potential return of 41.25% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -23.43%, Pretax Profit Margin comes in at -22.95%, and Net Profit Margin reading is -23.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.52 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.84 points at the first support level, and at 15.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.85, and for the 2nd resistance point, it is at 17.24.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] is 21.52. Also, the Quick Ratio is 21.52, while the Cash Ratio stands at 14.96. Considering the valuation of this stock, the price to sales ratio is 313.62, the price to book ratio is 4.34.
Transactions by insiders
Recent insider trading involved SAHA SAURABH, Chief Executive Officer, that happened on Jan 21 ’25 when 55000.0 shares were sold. Officer, SAHA SAURABH completed a deal on Jan 21 ’25 to buy 55000.0 shares. Meanwhile, General Counsel HUSSAIN IQBAL J sold 6000.0 shares on Jan 15 ’25.
